Ming Zheng
Ming Zheng
Correspondence to the editorial on "Targeting the ASB3-CPT1A axis-a new player in combating metabolic dysfunction-associated steatotic liver disease (CHM-2025-1013)" [0.03%]
关于“针对ASB3-CPT1A轴——对抗与代谢功能障碍相关脂肪肝病的新参与者(CHM-2025-1013)”的述评通信回复
Yuli Lin,Dongqin Yang,Zhihao Wu et al.
Yuli Lin et al.
Correspondence to the editorial "ASB3 degrades the gateway to β-oxidation: on Hepatocytic ASB3 deficiency alleviates MASLD by decreasing ubiquitin-mediated CPT1A" [0.03%]
关于编辑部评论“ASB3 降解β氧化之门户：肝细胞ASB3缺乏通过减少泛素介导的CPT1A降解来缓解MASLD”的回信
Dongqin Yang,Yuli Lin,Chunhua Song et al.
Dongqin Yang et al.
Distinct TIME Modulation by Anti-PD-1/PD-L1, VEGF, and CTLA-4 Blockade Provides a Rationale for Triplet Therapy in HCC [0.03%]
抗PD-1 / PD-L1，VEGF和CTLA-4阻断的不同时间调节为肝癌的三联疗法提供了理论依据
Hideki Iwamoto,Hironori Koga,Takumi Kawaguchi
Hideki Iwamoto
ASB3 Degrades the Gateway to β-Oxidation: Editorial on "Hepatocytic ASB3 deficiency alleviates MASLD by decreasing ubiquitin-mediated CPT1A" [0.03%]
ASB3降解β氧化通路的门控蛋白：关于“肝细胞ASB3缺乏通过降低UCPT1A加剧MASLD”的述评
Ho Jae Ryu,Ji Su Han,Ja Hyun Koo
Ho Jae Ryu
Reply to "Correspondence to Economic and Clinical Considerations for NC-MRI in Late HCC Recurrence Surveillance" [0.03%]
关于“NC-MRI用于晚期肝癌复发筛查的经济及临床价值评述”的回复
Qi-Feng Chen,Sui-Xing Zhong,Xiong-Ying Jiang et al.
Qi-Feng Chen et al.
Rethinking ACLF Prognosis: Can Machine Learning Outperform Conventional Scores? Editorial on: Predictive Machine Learning Model in ICU Patients with Acute-on-Chronic Liver Failure and Two or More Organ Failures [0.03%]
重新思考ACLF预后：机器学习能否超越传统评分？社论：重症监护室急性-on-慢性肝功能衰竭且有两个或更多器官功能障碍患者的预测性机器学习模型
Jung Hee Kim
Jung Hee Kim
Non-Contrast MRI Outperforms Contrast-Enhanced CT in Preoperative Detection of Hepatocellular Carcinoma: A Paired Validation Study [0.03%]
无对比剂磁共振比强化CT更有利于肝细胞癌的术前检测：配对验证研究
Laizhu Zhang,Weiwei Zong,Jialin Gao et al.
Laizhu Zhang et al.